The Hydrogen Sulfide-Vitamin B12-Folic Acid Axis: An Intriguing Issue in Chronic Kidney Disease. A Comment on Toohey JI: "Possible Involvement of Hydrosulfide in B12-Dependent Methyl Group Transfer". Molecules 2017, 22, 582, Pii: E582

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2017 Jul 30

PMID 28753969

Citations 2

Authors

Giuseppe Cianciolo

Maria Cappuccilli

Gaetano La Manna

Affiliations

Soon will be listed here.

Citing Articles

Vitamin B Supplementation and Nutritional Intake of Methyl Donors in Patients with Chronic Kidney Disease: A Critical Review of the Impact on Epigenetic Machinery.

Cappuccilli M, Bergamini C, Giacomelli F, Cianciolo G, Donati G, Conte D Nutrients. 2020; 12(5).

PMID: 32349312 PMC: 7281987. DOI: 10.3390/nu12051234.

Folic Acid and Vitamin B12 Administration in CKD, Why Not?.

Capelli I, Cianciolo G, Gasperoni L, Zappulo F, Tondolo F, Cappuccilli M Nutrients. 2019; 11(2).

PMID: 30781775 PMC: 6413093. DOI: 10.3390/nu11020383.

References

Wang R . Two's company, three's a crowd: can H2S be the third endogenous gaseous transmitter?. FASEB J. 2002; 16(13):1792-8. DOI: 10.1096/fj.02-0211hyp. View

Perna A, Ingrosso D, Violetti E, Luciano M, Sepe I, Lanza D . Hyperhomocysteinemia in uremia--a red flag in a disrupted circuit. Semin Dial. 2009; 22(4):351-6. DOI: 10.1111/j.1525-139X.2009.00579.x. View

Feng S, Li H, Wang S . Lower Hydrogen Sulfide Is Associated with Cardiovascular Mortality, Which Involves cPKCβII/Akt Pathway in Chronic Hemodialysis Patients. Blood Purif. 2015; 40(3):260-9. DOI: 10.1159/000439580. View

Li H, Feng S, Zhang G, Wang S . Correlation of lower concentrations of hydrogen sulfide with atherosclerosis in chronic hemodialysis patients with diabetic nephropathy. Blood Purif. 2014; 38(3-4):188-94. DOI: 10.1159/000368883. View

Harja E, Chang J, Lu Y, Leitges M, Zou Y, Schmidt A . Mice deficient in PKCbeta and apolipoprotein E display decreased atherosclerosis. FASEB J. 2008; 23(4):1081-91. PMC: 2660644. DOI: 10.1096/fj.08-120345. View

Collins A, Foley R, Chavers B, Gilbertson D, Herzog C, Ishani A . US Renal Data System 2013 Annual Data Report. Am J Kidney Dis. 2013; 63(1 Suppl):A7. DOI: 10.1053/j.ajkd.2013.11.001. View

Xu X, Qin X, Li Y, Sun D, Wang J, Liang M . Efficacy of Folic Acid Therapy on the Progression of Chronic Kidney Disease: The Renal Substudy of the China Stroke Primary Prevention Trial. JAMA Intern Med. 2016; 176(10):1443-1450. DOI: 10.1001/jamainternmed.2016.4687. View

Marti F, Vollenweider P, Marques-Vidal P, Mooser V, Waeber G, Paccaud F . Hyperhomocysteinemia is independently associated with albuminuria in the population-based CoLaus study. BMC Public Health. 2011; 11:733. PMC: 3188498. DOI: 10.1186/1471-2458-11-733. View

Perna A, Sepe I, Lanza D, Capasso R, Di Marino V, De Santo N . The gasotransmitter hydrogen sulfide in hemodialysis patients. J Nephrol. 2010; 23 Suppl 16:S92-6. View

10.

Debreceni B, Debreceni L . The role of homocysteine-lowering B-vitamins in the primary prevention of cardiovascular disease. Cardiovasc Ther. 2014; 32(3):130-8. DOI: 10.1111/1755-5922.12064. View

11.

House A, Eliasziw M, Cattran D, Churchill D, Oliver M, Fine A . Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial. JAMA. 2010; 303(16):1603-9. DOI: 10.1001/jama.2010.490. View

12.

de Koning L, Hu F . Homocysteine lowering in end-stage renal disease: is there any cardiovascular benefit?. Circulation. 2010; 121(12):1379-81. DOI: 10.1161/CIR.0b013e3181daa7c9. View

13.

Heinz J, Kropf S, Luley C, Dierkes J . Homocysteine as a risk factor for cardiovascular disease in patients treated by dialysis: a meta-analysis. Am J Kidney Dis. 2009; 54(3):478-89. DOI: 10.1053/j.ajkd.2009.01.266. View

14.

Cianciolo G, La Manna G, Coli L, Donati G, DAddio F, Persici E . 5-methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients. Am J Nephrol. 2008; 28(6):941-8. PMC: 2786016. DOI: 10.1159/000142363. View

15.

Ferreira J, Koyanagi T, Palaniyandi S, Fajardo G, Churchill E, Budas G . Pharmacological inhibition of βIIPKC is cardioprotective in late-stage hypertrophy. J Mol Cell Cardiol. 2011; 51(6):980-7. PMC: 3418885. DOI: 10.1016/j.yjmcc.2011.08.025. View

16.

Toohey J . Possible Involvement of Hydrosulfide in B-Dependent Methyl Group Transfer. Molecules. 2017; 22(4). PMC: 6154648. DOI: 10.3390/molecules22040582. View

17.

Welch G, Loscalzo J . Homocysteine and atherothrombosis. N Engl J Med. 1998; 338(15):1042-50. DOI: 10.1056/NEJM199804093381507. View

18.

Cheng X . Updating the relationship between hyperhomocysteinemia lowering therapy and cardiovascular events. Cardiovasc Ther. 2012; 31(4):e19-26. DOI: 10.1111/1755-5922.12014. View